TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06541314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Fluzoparib (50mg per capsule) 150mg po bid, with a treatment cycle of 28 days. Administer 2 cycles in total.
Study: NCT05171049

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Abelacimab
Description: Abelacimab 150 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: Apixaban 10 mg followed by 5 mg
Study: NCT04623775

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Specified dose on specified days
Study: NCT06692491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg,q2w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with pembrolizumab under the guidance of MTB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 10mg/kg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with durvalumab under the guidance of MTB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 10mg/kg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with durvalumab under the guidance of MTB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200mg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with atezolizumab under the guidance of MTB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200mg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with atezolizumab under the guidance of MTB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab 200mg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with sintilimab under the guidance of MTB.
Study: NCT04623775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
Study: NCT06692491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab 200mg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with sintilimab under the guidance of MTB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200mg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with tislelizumab under the guidance of MTB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200mg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with tislelizumab under the guidance of MTB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab 200mg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with camrelizumab under the guidance of MTB.
Study: NCT05009056

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Postsurgical computer guided functional appliance
Description: After achieving ideal condylar poison by computer guided surgery. The distal extension of the final occlusal wafer will be cut and the appliance will be fitted to be utilized as a postsurgical functional appliance for condylar adaptation. Patients will be instructed to wear the splints continuously for 3 months, only being allowed to remove them when eating and brushing their teeth.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Postsurgical computer guided functional appliance
Description: After achieving ideal condylar poison by computer guided surgery. The distal extension of the final occlusal wafer will be cut and the appliance will be fitted to be utilized as a postsurgical functional appliance for condylar adaptation. Patients will be instructed to wear the splints continuously for 3 months, only being allowed to remove them when eating and brushing their teeth.
Study: NCT05667597

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Humoral immunity
Description: determine binding and neutralizing antibody levels against the epidemiologically predominant SARS- CoV-2 variants of concern (VOC) and the wild type SARS-CoV-2 (Wuhan strain).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Humoral immunity
Description: determine binding and neutralizing antibody levels against the epidemiologically predominant SARS- CoV-2 variants of concern (VOC) and the wild type SARS-CoV-2 (Wuhan strain).
Study: NCT05984862

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bandage
Description: To determine if using bandage versus no-bandage, plays a role in limiting severity and duration of signs and symptoms of acute inflammation post follicular harvesting procedure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bandage
Description: To determine if using bandage versus no-bandage, plays a role in limiting severity and duration of signs and symptoms of acute inflammation post follicular harvesting procedure
Study: NCT06692491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab 200mg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with camrelizumab under the guidance of MTB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab 240kg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with toripalimab under the guidance of MTB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab 240kg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with toripalimab under the guidance of MTB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: Serplulimab 3mg/kg,q2w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with serplulimab under the guidance of MTB.
Study: NCT06212674

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PVI + LAAO
Description: Treatment with a complex procedure of PVI + LAAO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LAAO
Description: Tratment with LAAO procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NOAC
Description: NOAC treatment
Study: NCT06167850

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Copenhagen plank
Description: Performing Copenhagen adduction as prevention for adductor injury.
Study: NCT04956848

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iDAScore®
Description: Images of all the embryos reaching at least developmental stage of 3BB will be analyzed by iDAScore®. The embryo with the highest iDAScore® will be proposed for transfer.
Study: NCT05156086

Intervention type: DRUG
Intervention: COVID-19 vaccine, booster
Description: Additional dose of COVID-19 vaccine (booster shot)
Study: NCT06696183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax (VEN)
Description: 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax (VEN)
Description: 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine (AZA)
Description: 75 mg/m²

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine (AZA)
Description: 75 mg/m²

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine (AZA)
Description: 75 mg/m²

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine (AZA)
Description: 75 mg/m²
Study: NCT06696131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNK
Description: TNK will be delivered into the site of the intracerebral hemorrhage via a brain catheter.
Study: NCT06696352

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partners4Pain
Description: This is a group program that will teach participants about different things they can do to manage their pain. They will watch educational videos and do workbook activities. They will learn and practice different exercises and mind-body strategies for pain including back and neck exercises (like strengthening and stretching), mind-body exercises (like meditation, relaxed breathing, guided imagery, and muscle relaxation), problem solving, and how to communicate with others about your pain. They will also have an opportunity to take part in discussions with other group members. The program will be delivered via weekly 90 minute sessions over 9 weeks and will be offered in-person or via videoconference.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Keys to Wellbeing
Description: This is a group program that will teach participants about different things they can do to improve their health and wellbeing. Participants will watch educational videos and do workbook activities. They will learn different back and neck exercises (like strengthening and stretching) and be introduced to different health-related topics including information and tips about health, pain and wellbeing; keeping active and well; the importance of rest and relaxation; and working with meaning and purpose in your life. They will also have an opportunity to take part in discussions with other group members. The program will be delivered in weekly 90 minute sessions over 9 weeks and will be offered in-person or via videoconference.
Study: NCT06697886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiwei Granules
Description: During the 3-day treatment period, participants will receive 9 sacks of Antiwei granules. Oral administration, 1 sack (6g) per time, 3 times daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antiwei Granules Placebo
Description: During the 3-day treatment period, participants will receive 9 sacks of Antiwei granules. Oral administration, 1 sack (6g) per time, 3 times daily.
Study: NCT06692491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: Serplulimab 3mg/kg,q2w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with serplulimab under the guidance of MTB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Adebrelimab 20mg/kg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with adebrelimab under the guidance of MTB.
Study: NCT06697899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TGRX-678
Description: All participants are given TGRX-678 orally at 240 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TGRX-678
Description: All participants are given TGRX-678 orally at 240 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TGRX-678
Description: All participants are given TGRX-678 orally at 240 mg
Study: NCT06492486

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adaptive radiotherapy
Description: Volumetric and biological adaptive radiotherapy will be delivered based on interval imaging with MRI and PET scan during treatment.
Study: NCT05951205

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Exa-cel
Description: Administered by intravenous (IV) infusion following myeloablative conditioning with busulfan.
Study: NCT06125002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diosmin750
Description: The ingestion will occur orally, under monitoring by the responsible investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The ingestion will occur orally, under monitoring by the responsible investigator.
Study: NCT06291454

Intervention type: DIAGNOSTIC_TEST
Intervention: Routine periodontal examination
Description: In all of the patients, the following indexes were used routinely for the periodontal examination: Sillness-Löe's plaque index (PI) (Silness \& Löe, 1964), Löe-Sillness's gingival index (GI)(Löe \& Silness, 1963), probing depth (PD) to measure the extent and severity of periodontal disease, clinical attachment level (CAL), and bleeding on probing (BOP)(Ainamo \& Bay, 1975) to determine activity. In addition, routine radiographic evaluations were performed to determine bone levels.GCF samples were collected using standardized filter papers.

Intervention type: DIAGNOSTIC_TEST
Intervention: Routine periodontal examination
Description: In all of the patients, the following indexes were used routinely for the periodontal examination: Sillness-Löe's plaque index (PI) (Silness \& Löe, 1964), Löe-Sillness's gingival index (GI)(Löe \& Silness, 1963), probing depth (PD) to measure the extent and severity of periodontal disease, clinical attachment level (CAL), and bleeding on probing (BOP)(Ainamo \& Bay, 1975) to determine activity. In addition, routine radiographic evaluations were performed to determine bone levels.GCF samples were collected using standardized filter papers.

Intervention type: DIAGNOSTIC_TEST
Intervention: Routine periodontal examination
Description: In all of the patients, the following indexes were used routinely for the periodontal examination: Sillness-Löe's plaque index (PI) (Silness \& Löe, 1964), Löe-Sillness's gingival index (GI)(Löe \& Silness, 1963), probing depth (PD) to measure the extent and severity of periodontal disease, clinical attachment level (CAL), and bleeding on probing (BOP)(Ainamo \& Bay, 1975) to determine activity. In addition, routine radiographic evaluations were performed to determine bone levels.GCF samples were collected using standardized filter papers.
Study: NCT06660277

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Super High-Flux Dialyzer
Description: Dialyzer currently approved and available for use across Canada.
Study: NCT06676813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alternate day fasting
Description: Alternate day fasting
Study: NCT06677905

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: web-based spinal cord injury self-management program
Description: Peer health coaches will be recruited from the United Spinal Connecticut Chapter and SCI BC. They will be at least 5 years post-SCI and will be certified in brief action planning and in Mental Health First Aid.~Online coaching sessions are expected to cover a health-related topic (eg. bladder, bowel, skin, pain, healthy eating, physical activity or stress, anxiety and depression etc) and a self-management skill topic (eg.action planning, goal setting, problem-solving, mood management, navigating the health care system, communicating with health care providers). To ensure we meet the unique needs of participants, the coach and participant will determine jointly how many sessions to spend on a topic. In addition, coaches will be able to link relevant information and resources contained in the resource library to each session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer support
Description: Existing peer support program from the United Spinal Connecticut Chapter or SCI BC
Study: NCT06660277

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-Flux Dialyzer
Description: Dialyzer that is widely used across Canada for hemodialysis treatments.
Study: NCT06438757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JYB1904
Description: Participants will receive JYB1904 every 8 weeks for 24 weeks.
Study: NCT06658574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Arm 1: Once cleared for oral intake - acetaminophen tablets 650 mg PO every 6 hours PRN - mild pain (1 - 3) to a maximum of 4 grams daily for 3 days\&#39; dispensed as unit-dose tablets Arm 2: Once cleared for oral intake - acetaminophen liquid (160 mg/5 mL) 650 mg PO every 6 hours PRN - mild pain (1 - 3) to a maximum of 4 grams daily for 3 days; 650 mg = 20.3 mL, dispensed as a unit-dose cup

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Arm 1: Once cleared for oral intake - acetaminophen tablets 650 mg PO every 6 hours PRN - mild pain (1 - 3) to a maximum of 4 grams daily for 3 days\&#39; dispensed as unit-dose tablets Arm 2: Once cleared for oral intake - acetaminophen liquid (160 mg/5 mL) 650 mg PO every 6 hours PRN - mild pain (1 - 3) to a maximum of 4 grams daily for 3 days; 650 mg = 20.3 mL, dispensed as a unit-dose cup
Study: NCT06034327

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single vision, impact-resistant spectacle lenses; Test Arm
Description: Use of single vision, impact-resistant spectacle lenses may reduce the rate of progression of juvenile myopia

Intervention type: DEVICE
Group type: OTHER
Intervention: Single vision, impact-resistant spectacle lenses; Control Arm
Description: Single vision, impact-resistant spectacle lenses
Study: NCT04834752

Intervention type: OTHER
Intervention: No intervention (Retrospective Cohort Observational)
Description: History of PPI and H2RA prescription of the participants who were tested for COVID-19 will be reviewed.
Study: NCT06598033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VC plus herbal medicine
Description: Vitamin C 300 mg/day, TID, PO. Reishi, 2 g/day, BID, PO. Cordyceps, 2 g/day, BID, PO.
Study: NCT06692491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Adebrelimab 20mg/kg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with adebrelimab under the guidance of MTB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: Envafolimab 150mg,qw Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with envafolimab under the guidance of MTB.
Study: NCT05974358

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kono-S anastomosis
Description: Kono et al. described a new operative technique that could reduce the rate of post-operative recurrence: a termino-terminal ileocolonic anastomosis, anti-mesenteric, with a supporting column to prevent distortion and anastomotic stenosis (Kono-S anastomosis).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional anastomosis for ileocolonicresection of Crohn's disease
Description: conventional anastomosis for ileocolonicresection of Crohn's disease
Study: NCT06692491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: Envafolimab 150mg,qw Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with envafolimab under the guidance of MTB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib 80mg,qd Patients with advanced rare tumours who failed to standard treatment carrying EGFR mutations will be administrated with osimertinib under the guidance of MTB.
Study: NCT06618638

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared decision making model
Description: Shared decision making model for choosing pharmacotherapy in ADPKD patients. This newly developed shared decision making model follows the SHARE approach and includes patient education, identifying values and preferences, reaching a decision and evaluating.